Exhibit 99.1

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting | June 25, 2021 www.acimmune.com Version: 22.06.2021

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contains statements that constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Forward - looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations . In some cases, you can identify these statements by forward - looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology . Forward - looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements . These risks and uncertainties include those described under the captions “Item 3 . Key Information – Risk Factors” and “Item 5 . Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20 - F and other filings with the Securities and Exchange Commission . These include : the impact of Covid - 19 on our business, suppliers, patients and employees and any other impact of Covid - 19 . Forward - looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law . All forward - looking statements are qualified in their entirety by this cautionary statement . This presentation is strictly confidential, is being distributed to a limited range of invited persons solely for their own information, may not be distributed to the press or any other person, and may not be reproduced or published, in whole or in part, in any form . SupraAntigen ® and Morphomer ® are registered trademarks of AC Immune SA in the following territories : AU, CH, EU, JP, and GB . Morphomer ® is also a registered trademark of AC Immune SA in CN and NO . 2

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 3 Agenda 1. AC Immune’s leadership in neurodegenerative diseases 2. Achievements 2020/21 3. AC Immune’s business strategy 4. Pipeline update 5. SupraAntigen™ and clinical - stage vaccine programs 6. Near - term inflection points 7. Financial figures 8. Strategic outlook

1. AC Immune’s leadership in neurodegenerative diseases Andrea Pfeifer, CEO

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 2013 2014 2015 2017 2019 2020 2020 2021 2021 (1) Neurodegenerative diseases; (2) Alzheimer's disease; (3) Phosphorylated Tau; (4) Positron emission tomography; (5) Progre ssi ve supranuclear palsy; (6) Small molecule Tau - specific aggregation inhibitor; (7) TAR DNA binding protein - 43; (8) Alpha synuclein Anti - pTau 3 vaccine clinical trial in AD 1 st 1 st Clinical vaccine trial in Down syndrome (Abeta vaccine) Anti - TDP - 43 7 antibody shown to mitigate TDP - 43 neuropathology 1 st Prevention trial in AD 2 (crenezumab) 1 st 1 st Clinical data for Tau PET 4 - imaging tracer in PSP 5 1 st Morphomer ® Tau 6 clinical trial (ACI - 3024) Anti - Tau antibody Phase 2 readout in AD; target engagement 1 st “Firsts” reflect ACIU’s leadership in NDD 1 1 st Small molecule a - syn 8 aggregation inhibitor 1 st First - in - human clinical study of diagnostic a - syn PET tracer 5

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Precision medicine is a key driver for effective treatments Roadmap to successful therapies for neurodegenerative diseases 6 ( 1 ) Reardon S, Nature 2018 ; ( 2 ) Pontecorvo MJ, et al . , Brain 2019 ; ( 3 ) Gordon BA, et al . , Brain 2019 ; ( 4 ) Positron emission tomography ; ( 5 ) Strydom A, et al . , Alzheimers Dement (NY) 2018 ; ( 6 ) Lott IT and Head E . , Nat Rev Neurol . 2019 ; ( 7 ) Down syndrome - related Alzheimer’s disease ; ( 8 ) TAR DNA - binding protein 43 ; ( 9 ) Robinson JL, et al . , Brain 2018 ; ( 10 ) Heneka MT et al . , Nat Rev Neurosci . 2018 ; ( 11 ) Wang S et al . , Int Immunopharmacol . 2019 ; ( 12 ) Monoclonal antibody ; ( 13 ) Small molecule ; ( 14 ) ( NOD) - like receptor protein 3 ; ( 15 ) Apoptosis - associated speck - like protein containing a CARD, also PYCARD ▪ Familial Alzheimer’s disease, Down syndrome 7 ▪ NeuroOrphan indications, specifically TDP - 43 8 - and Tau - driven ▪ Diagnose co - pathologies with selective diagnostics ▪ Select and treat study population based on specific proteinopathies Treat earlier 1 More homogeneous populations 5,6 Precision medicine 9 Target neuroinflammation 10,11 ▪ Prioritize primary and secondary prevention trials ▪ Access diagnostic tools for patient identification ▪ Develop mAb 12 and sm 13 for microglial balance targeting the inflammasome NLRP3 14 - ASC 15 pathway Target Tau 2,3 ▪ Target both intracellular Tau and Tau spreading ▪ Use Tau PET 4 to diagnose and select patients and define treatment effects

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Precision medicine for prevention and treatment of NDD 7 Ref : Jack et al.; Lancet Neurology 2010; Trojanowski et al., Alzheimer's & Dementia 2010; Jansen et al .; JAMA. 2015 Cognitively normal MCI Dementia Normal Abnormal Onset of pathologies Cognitive impairment (1) Cerebrospinal fluid; (2) Positron emmision tomography; (3) Phosphoylated Tau; (4) Magnetic resonance imaging; (5) Fluorod eox yglucose; (6) Prodromal: mild cognitive impairment (MCI) with biomarker evidence – approx. 60% of MCI Adapted from Mattsson - Carlgren et al Sci Adv 2020 Vaccine Small molecule Antibody Treatment Prevention Interventions: - 20 - 10 - 5 - 25+

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission The need for precision medicine 8 Improved clinical trials, diagnosis and treatment of neurodegenerative diseases Co - pathologies in AD 1 and other NDD 2 may indicate a need for different therapies at different stages 1 Patients selected and treated according to their underlying pathologies 2 Non - invasive diagnostics are critical for monitoring disease progression 3 Combination therapy may be the ultimate requirement 4 Earlier, more reliable diagnosis may eventually lead to disease prevention 5 ■ Treating the right proteinopathies, in the right patient, at the right time 35% iAD 5 32% 24% 9% 33% TDP - 43 41% a - syn 30% hAD 6 30% 15% 25% 40% TDP - 43 55% a - syn Pure Tau and Abeta TDP - 43 + a - syn a - syn 4 TDP - 43 3 Adapted from Robinson et al, Brain, 2018 (1) Alzheimer’s disease; (2) Neurodegenerative diseases; (3) TAR DNA - binding protein 43; (4) Al pha - synuclein; (5) Intermediate level of Alzheimer’s disease neuropathological change; (6) High level of Alzheimer’s disease neuropathological change

2. Achievements 2020/21

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Strong progress in 2020 10 Continuing our track record of successful execution x Received second milestone payment of CHF 10 million from Lilly for small molecule Tau aggregation inhibitor x Awarded two highly competitive grants to accelerate development of first - in - class TDP - 43 1 diagnostics: ▪ EU JPND 2 : PET 3 tracer to visualize TDP - 43 pathology in the brain; in partnership with the ImageTDP - 43 consortium ▪ Target ALS 4 : immuno - assays to detect pathological TDP - 43 in CSF 5 and blood; in collaboration with the Healy Center for ALS at Massachusetts General Hospital Achieving partnership milestones and grants Advancing development pipeline x Reported top line Phase 2 results for anti - Tau antibody in prodromal to mild AD 6 x Advanced to second highest dosing cohort in Phase 1b/2a study of anti - Tau vaccine x Started IND 7 - enabling studies for lead anti - a - syn 8 and anti - TDP - 43 antibody candidates Further establishing thought leadership x Appointed Prof. Johannes R. Streffer , former UCB Biopharma Head of Translational Neuroscience, as CMO 9 x Appointed Prof. Carl H. June, world authority on immune tolerance and adoptive immunotherapy, to Board of Directors x Appointed renowned Neurologist with a specific focus in the emerging field of Down syndrome - related Alzheimer’s disease, Dr. Juan Fortea to Clinical Advisory Board Unlocking additional value x Strengthened strategic partnership with WuXi Biologics to accelerate advancement of TDP - 43 antibody into clinical development for NeuroOrphan indications x Reported proof - of - concept data for lead candidates in therapeutic and diagnostic programs targeting TDP - 43 and a - syn x Reported enhanced performance of first - in - class a - syn PET tracer at AAIC (1) TAR DNA - binding protein 43; (2) Joint Programme – Neurodegenerative Disease Research; (3) Positron emission tomography; (4) Amyotrophic lateral sclerosis; (5) Cerebrospinal fl uid; (6) Alzheimer’s disease; (7) Investigational new drug; (8) Alpha - synuclein; (9) Chief medical officer

3. AC Immune’s business strategy

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Execution of our three - pillar strategy: the 2021 focus 12 Precision medicine Alzheimer’s disease (AD) Focused non - AD Parkinson’s 1 LATE 2 NeuroOrphan Diagnostics SupraAntigen ® & Morphomer ® Values Alzheimer’s disease ▪ Accelerate development of phospho - Tau vaccine with partner Janssen ▪ Prioritize development of small molecule Tau aggregation inhibitor with partner Lilly (1) Parkinson’s disease; (2) Limbic - predominant age - related TDP - 43 encephalopathy, a TDP - 43 - dependent dementia that affects 20% - 50% of individuals >80 years old; (3) Down syndrome - related Alzheimer’s disease; (4) TAR DNA - binding protein 43; (5) Monoclonal antibody; (6) Amyotrophic lateral sclerosis; (7) Frontotemporal lobar degeneratio n with TDP - 43 pathology; (8) Alpha - synuclein; (9) (NOD) - like receptor protein 3; (10) Central nervous system Non - AD and NeuroOrphans ▪ Advance Abeta vaccine in Down syndrome 3 to late stage; seek partner for AD ▪ Advance anti - TDP - 43 4 mAb 5 in NeuroOrphan indications (ALS 6 , FTLD - TDP 7 ) ▪ Accelerate a - syn 8 small molecule in Parkinson’s disease ▪ Develop NLRP3 9 assets in CNS 10 and non - CNS indications Diagnostics for precision medicine ▪ Advance differentiated diagnostic pipeline (Tau, a - syn, TDP - 43) to late stage ▪ Early detection, improved clinical trials and marked differentiation

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Vision to become a global leader in precision medicine 1 13 Developing breakthrough mono - and combination therapies for neurodegenerative diseases SupraAntigen ® Vaccines and antibodies specific to disease causing conformations Morphomer ® Conformation - sensitive small molecules Clinically Validated Technology Platforms Images: Hickman et al. , JBC 2011; Kroth et al., JBC 2012 (1) The goal of precision medicine is to deliver optimally targeted and timed interventions tailored to the individual disease drivers

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission SupraAntigen ® and Morphomer ® platforms An integrated approach to CNS 1 - specific therapies 14 (1) Central nervous system Clinically validated CNS - optimized Precision medicine enabling Conformation - specific SupraAntigen ® Morphomer ® Vaccines & Antibodies Small Molecules

4. Pipeline update

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Broad and robust pipeline in neurodegenerative diseases Driven by validated proprietary technology platforms for sustained growth 16 TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNER Tau ACI - 35.030 (anti - pTau vaccine ) AD 1 treatment Semorinemab (anti - Tau antibody) AD treatment ( moderate) Morphomer ® Tau aggregation inhibitor Rare Tauopathies (ACI - 3024) AD treatment Tau - PET 2 tracer AD diagnostic PSP 3 diagnostic Abeta Crenezumab (anti - Abeta antibody) AD prevention 4 ACI - 24 (anti - Abeta vaccine) AD treatment ( Down syndrome 5 ) AD treatment Biologic Small Molecule Diagnostic (1) Alzheimer’s disease; (2) Positron emission tomography; (3) Progressive supranuclear palsy; (4) Prevention trial API - ADAD in Colombia; (5) Down syndrome - related Alzheimer’s disease Established Targets Pipeline

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 a - synuclein (a - syn) A - syn - PET 3 tracer PD 4 , a - synucleinopathies Anti - a - syn antibody PD, NeuroOrphan Morphomer ® a - syn (a - syn inhibitor) PD, a - synucleinopathies TDP - 43 Anti - TDP - 43 5 antibody LATE 6 , NeuroOrphan TDP - 43 - PET tracer TDP - 43 - opathies Inflammasome Anti - NLRP3 7 - ASC 8 antibody NeuroOrphan Morphomer ® NLRP3 - ASC Non - CNS Morphomer ® NLRP3 - ASC NeuroOrphan Broad and robust pipeline in neurodegenerative diseases Diversification into non - AD 1 and non - CNS 2 diseases 17 Biologic Small Molecule Diagnostic (1) Alzheimer’s disease; (2) Central nervous system; (3) Positron emission tomography; (4) Parkinson’s disease; (5) TAR DNA - bind ing protein 43; (6) Limbic - predominant age - related TDP - 43 encephalopathy; (7) ( NOD) - like receptor protein 3; (8) Apoptosis - associated speck - like protein containing a CARD, also PYCARD Novel Targets Pipeline

5. SupraAntigen ® platform and Clinical vaccine programs

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Proprietary SupraAntigen ® platform Generation of vaccines and monoclonal antibodies 19 Antibodies: Passive immunization (external antibody production) Vaccines: Active immunization (immune system produces antibodies) (1) Synthetic Monophosphoryl Lipid A; (2) Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs SupraAntigen ® - V SupraAntigen ® - A Liposomal anchor (Palmitic chains) Liposomal bilayer (Cholesterol and phospholipids) Adjuvant (MPLA 1 ) Target antigen (B - cell peptide) T - cell Peptide (non - target) Adjuvant (CpG 2 ) Adjuvants and other liposome components are optimized for each specific application

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission SupraAntigen ® : Key advantages/benefits 20 CANDIDATE DISCOVERY PRE - CLINICAL PH 1 PH 2 ACI - 35.030 (anti - pTau vaccine ) Semorinemab (anti - Tau antibody ) Crenezumab (anti - Abeta antibody) ACI - 24 for DS (anti - Abeta vaccine) ACI - 24 for AD (anti - Abeta vaccine) Anti - a - syn antibody Anti - TDP - 43 5 antibody Anti - NLRP3 6 - ASC 7 antibody SupraAntigen ® Programs Antibody Vaccine (1) Alzheimer’s disease; (2) Positron emission tomography; (3) Progressive supranuclear palsy; (4) Alpha - synuclein; (5) TAR DNA - binding protein 43; (6) ( NOD) - like receptor protein 3; (7) Apoptosis - associated speck - like protein containing a CARD, also PYCARD Key advantages: ▪ Liposomal technology enables conformation - specific targeting ▪ Antibodies: high affinity, high target specificity ▪ Vaccines: potent, polyclonal, T - cell independent (for target) ▪ Proprietary suite of assays to validate successful candidates ▪ Clinically validated Proprietary technology: External antibody production with frequent injections Immune system produces antibodies over long period SupraAntigen ® - A Antibodies: Passive immunization SupraAntigen ® - V Vaccines: Active immunization

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 21 Key results 2 ▪ Highly specific antibody response against aggregated pTau ▪ Preclinical: improvement of cognition, physical performance, behavior and survival; T - cell independent mode of action (Tau) ▪ Clinical: dose - dependent, pTau - specific antibody response (Phase 1b) Phase 1b/2a design ▪ Randomized, multicenter, double - blind, placebo - controlled ▪ 32 patients (MMSE 5 ≥ 22, CDR - GS 6 of 0.5 or 1); 3 different doses and regimens for 48 weeks; 6 - month follow - up ▪ Primary endpoints: safety, tolerability and immunogenicity; other endpoints: CDR - SB 7 ; RBANS 8 ; at week 74 Development status ▪ Vaccine achieves high titers of antigen - specific antibodies in 100% of patients with early AD ▪ Interim Phase 1b/2a results (first two dosing groups) support plans to further develop into Phase 2b/3 Upcoming milestones Q1 Q2 Q3 Q4 Milestone ACI - 35.030 interim results (mid - dose) 9 ACI - 35.030 interim analysis (highest dose) 9 JACI - 35.054 10 interim analysis (low dose) 9 ACI - 35.030: anti - pTau vaccine – Phase 1b/2a in AD 1 (1) Alzheimer’s disease; (2) Refers to clinical candidate ACI - 35; (3) Transgenic mice, Tau.P301L; (4) Wild type mice; (5) Mini - mental state examination; (6) Clinical Dementia Rating Global Score; (7 ) Clinical Dementia Rating Sum of Boxes; (8) Repeatable Battery for the Assessment of Neuropsychological Status; (9) Safety, tolerability and immunogenicity; (10) Alt ern ative pTau vaccine SupraAntigen ® platform Highly significant improvement of behavior (P301S) 2 Immune response highly specific to phosphorylated Tau 2 ACI - 35 vaccinated mice - p Tau vs Tau protein after 5 immunizations 15 rpm ACI - R - 40 Rotarod 5M vehicle vs ACI - 35 4 3 AC Immune unpublished data Theunis et al., 2013 PLOS one

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission ACI - 35.030 – highly encouraging interim Phase 1b/2a results in AD 1 Achieved high titers of anti - pTau antibodies at potentially therapeutic levels in 100% of patients 22 (1) Alzheimer’s disease; (2) safety/tolerability and immunogenicity AC - 35.030 ▪ pTau selective ▪ T - cell independent (Tau) ▪ Optimized formulation SupraAntigen ® platform Interim results to date (safety/tolerability, immunogenicity): ▪ Anti - Tau IgG response preferentially targeting phosphorylated Tau in all patients ▪ 100% of patients demonstrated an anti - pTau IgG response after the 1 st injection ▪ Very high anti - pTau IgG titers observed following injections ▪ Anti - pTau IgM response was also elicited in all patients ▪ ACI - 35.030 was safe and well tolerated with n o vaccine - relevant safety concerns observed to date Mid dose Low dose ACI - 35.030 study arms: Q4 2021 Q1 2021 Q3 2020 ■ ACI - 35.030 generates unprecedented antibody responses against pTau in an older population ■ Strong safety and robust immunogenicity support advancing to Phase 2/3 High dose 48w 74w 48w 74w 48w 74w Follow up period Vaccination period Interim analysis 2

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Upcoming milestones Q1 Q2 Q3 Q4 Milestone Phase 2 interim analysis (12 month) in Alzheimer’s disease Phase 2 interim analysis (18 month) in Alzheimer’s disease 23 Key results 2 ▪ Strong and robust antibody response 2 ; specific for oligomers and fibrils ▪ Favorable safety profile with lack of local inflammation; T - cell independent mode of action ▪ Complete memory restoration and significant reduction of Abeta plaques in AD mouse model 4 ▪ Clinical: dose - dependent anti - Abeta IgG response and reduction of brain amyloid (Phase 1/2a) Phase 2 design ▪ Randomized, multi - center, double - blind, placebo - controlled, adaptive design study in mild AD ▪ 18 patients (MMSE 7 of 20 - 28); 8 injections over 74 weeks; 6 - month follow - up ▪ Primary endpoints: safety, tolerability, immunogenicity, amyloid PET; other endpoints: CDR - SB 8 ; ADAS - cog 13 9 ; MMSE; blood/CSF biomarkers (Abeta; Tau; pTau) Development status ▪ Fully recruited; 12 - month interim data (reported in Q1 2021) showed good safety and tolerability; no ARIA - E or – H 10 ▪ 18 - months interim data is expected in Q2 2021 ACI - 24 – Phase 2 in AD 1 - Anti - Abeta therapeutic vaccine Abeta PET 5 exploratory analysis Change in composite summary SUVR - MCG 6 Improvement Memory restoration (ORT) 3 in AD model 4 Muhs et al , PNAS 2007 KOL event, NYC, July 2019 SupraAntigen ® platform (1) Alzheimer's disease; (2) Pihlgren et al., Blood 2013; (3) Object recognition test; (4 ) APP/PS1 mouse model of AD; (5 ) Florbetaben positron emission tomography; (6) Standardized Uptake Value Ratio - Mean Cerebellar Gray; (7) Mini - mental state examination; (8) Clinical Dementia Rating Sum of Boxes; (9) Alzheimer's Disease Assessment Scale – Cognitive Subscale version 13; (10) Amyloid - rela ted imaging abnormalities - edema, - hemorrhage

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Study rationale ▪ DS population is at high risk of developing Alzheimer’s disease - like symptoms ▪ 75 – 100% of people with DS have Alzheimer’s disease - like symptoms by age 60 2 ▪ Unique possibility to study prevention and treatment of Alzheimer’s disease in a defined genetic population Key results ▪ Compelling memory enhancement in ORT 3 in DS mouse model Development status ACI - 24 in DS: Clinical Phase 1b ▪ World’s first clinical trial for vaccine targeting Abeta in people with DS ▪ Dose escalation study in up to 24 adults with DS (25−45 years) ▪ Primary endpoints: safety, tolerability, and immunogenicity; secondary endpoints: clinical, cognitive measures and biomarkers ▪ Top line data in Q1 2021: good safety and tolerability, encouraging immunogenicity and pharmacodynamic effect observed ACI - 24 – Phase 1b in people with Down syndrome (DS) 1 Anti - Abeta therapeutic vaccine 24 (1) Addressing - related Alzheimer’s disease; (2) Strydom et al., Alzheimer's Dement (N Y) 2018; (3) Object recognition test; (4) Autosomal dominant Alzheimer’s disease; (5) Memory restoration in a DS - relevant mouse model (TS65Dn) Memory restoration 5 Alzheimer’s disease in DS Similar pathophysiology and biomarkers in DS and ADAD 4 Belinchenko et al. , PLOS ONE 2016 ADAD, adapted from Bateman, NEJM 2012 DS, Fortea , AAIC 2019 SupraAntigen ® platform Upcoming milestones Q1 Q2 Q3 Q4 Milestone Top line Phase 1b results in people with Down syndrome Submit IND for optimized vaccine formulation

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Key results ▪ Primes, boosts and maintains polyclonal anti - Abeta IgG 2 response in two species of non - human primates (NHPs) ▪ Generates conformation - specific antibody responses targeting pathological Abeta oligomers ▪ Clear target engagement on human AD patient - derived tissue Development status ▪ Completing investigational new drug (IND) - enabling studies ▪ Expect to file IND followed by accelerated clinical development; rapid advancement to Phase 2 in Down syndrome Optimized anti - Abeta ACI - 24 vaccine formulation 25 (1) Alzheimer's disease; (2) Immunoglobulin G; (3 ) Immunohistochemistry Strong immune response against pathological Abeta(1 - 42) oligomers SupraAntigen ® platform Confirmed target engagement IHC 3 on AD patient - derived brains AC Immune unpublished data Generates enhanced immune response against pathological Abeta(1 - 42) oligomers NHP serum (pre - immune control) NHP serum (Day 64) Abeta Abeta Anti - Abeta response increases over time Upcoming milestones Q1 Q2 Q3 Q4 Milestone Submit IND for optimized vaccine formulation

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Optimized anti - Abeta ACI - 24: Strong immune response against pyroglutamate Abeta 26 Ref.: AC Immune; Global Down Syndrome Forum 2021 (1) Pyroglutamate Cynomolgus serum – Day 120 Epitope mapping Immunized cynomolgus sera ■ Sustained and enhanced IgG response that binds Abeta(1 - 42) and pyroglutamate Abeta, the truncated form of pathological Abeta ■ The optimized vaccine represents a potential breakthrough compared to previous anti - Abeta vaccines Ref.: Jawhar S et al,; J of Biol Chem 2011

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Optimized anti - Abeta ACI - 24: Superior recognition of pyroglutamate Abeta in NHPs 1 27 Broader N - terminal sequence recognition compared to previous clinical - stage Abeta vaccines ■ The optimized vaccine represents a potential breakthrough compared to previous anti - Abeta vaccines ■ Superior binding to oligomeric and truncated pyroglutamate Abeta may result in high levels of amyloid plaque clearance and neuroprotection Generates higher antibody titers against pyroglutamate Abeta (1) Non - human primates Vaccine - induced antibodies recognize a broader range of N - terminal Abeta epitopes Opt. ACI - 24 D120 AN1792 D91 ACC - 001 D120 Opt. ACI - 24 D120 AN1792 D91 ACC - 001 D120 Ref.: AC Immune unpublished data

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Disruptive potential of SupraAntigen ® - V Optimized vaccines delivering superior results in neurodegenerative diseases 28 (1) Synthetic Monophosphoryl Lipid A; (2) Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs; (3) 100% response after 1 st injection; (4) Increases over time ■ Robust immunogenicity and strong safety demonstrated in humans ■ Evidence for lasting immune response supporting a disease prevention approach Immunogenicity ++++ 3 Target specificity ++++ 4 Conformation specificity +++ Avidity increase over time +++ Sustainability of response +++ Boosting +++ Class switching IgM to IgG +++ Evidence of memory B cells +++ Unprecedented Clinical Performance Liposomal anchor (Palmitic chains) Liposomal bilayer (Cholesterol and phospholipids) Adjuvant (MPLA 1 ) Target antigen (B - cell peptide) T - cell Peptide (non - target) Adjuvant (CpG 2 ) Generates target - specific antibody response Safely engages target - unrelated T - cells to enhance & maintain response

6. Near - term inflection points

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 30 Multiple catalysts to drive further value creation in 2021 Q1 Q2 Q3 Q4 Clinical Tau pTau vaccine Interim Phase 1b/2a results (mid - dose) 1 of ACI - 35.030 Phase 1b/2a interim analysis (highest dose) 2 of ACI - 35.030 Phase 1b/2a interim analysis (low dose) of JACI - 35.054 3 Semorinemab (anti - Tau antibody) Phase 2 primary completion 4 ACI - 3024 Morphomer ® Tau Select NeuroOrphan indication Abeta ACI - 24 (anti - Abeta vaccine) Top line Phase 1b results in people with Down syndrome Phase 2 interim analysis (12 month) 5 in Alzheimer’s disease Phase 2 interim analysis (18 month) 5 in Alzheimer’s disease Submit IND for optimized vaccine formulation a - syn 6 PET 7 tracer First - in - human study initiation First - in - human study readout Preclinical Morphomer ® therapeutic Start in vivo proof - of - concept studies TDP - 43 8 PET tracer Initiate IND - enabling studies Anti - TDP - 43 antibody Initiate IND - enabling toxicology studies Biofluid diagnostic Establish validation ready assay Inflamm. 9 Morphomer ® NLRP3 10 - ASC 11 Report in vivo proof - of - concept in non - CNS 12 disease model Start in vivo proof - of - concept studies (CNS) Anti - NLRP3 - ASC antibody Start in vivo proof - of - concept studies = Biologic = Small molecule = Diagnostic = Achieved (1) Cohort 1.2: safety/tolerability and immunogenicity; (2) Cohort 1.2: safety/tolerability and immunogenicity; (3) Alternative pTau vaccine; (4) LAURIET study in moderate Alzheimer’s disease estimated last patient, last visit; (5) Safety/tolerability; (6) Alpha - synuclein; (7) Positron emission tomography; (8) TAR DNA - binding protein 43; (9) Inflammasome; (10) ( NOD) - like receptor protein 3; (11) Apoptosis - associated speck - like protein containing a CARD, also called PYCARD; (12) Central nervous system

7. Financial figures

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Substantial funds from partnerships complement equity investments 32 Distinguished institutional investors 1 Five private financing rounds IPO NASDAQ September 2016 Share capital offering of 10 million common shares July 2018 Upfront payments Milestone payments Partner equity investments 128.5 CHF 334 million CHF 313 million (1) Based on latest schedule 13G and 13F filings; (2) Converted to CHF based on exchange rates at times of receipt; (3) Miles ton e payments as of June 30, 2020; (4) With Lilly convertible loan ▪ CHF 313 million from investor funds ▪ CHF 334 million in partnering related funds 3,4 ▪ CHF 3 billion in total potential payments plus potential royalties outstanding Corporate funding to date 2 (in CHF millions)

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 33 First Quarter 2021 financial update Strong cash position R&D expenses G&A expenses Other operating income ▪ CHF 216.1 million at March 31, 2021, compared to CHF 225.9 million at December 31, 2020 ▪ Decreased by CHF 1.9 million to CHF 13.3 million for the quarter ended March 31, 2021 compared to 2020 ▪ Decreased by CHF 0.2 million to CHF 4.3 million for the quarter ended March 31, 2021 compared to 2020 ▪ Recognized CHF 0.4 million in grant income, an increase of CHF 0.3 million compared to the prior period Sufficiently funded to reach multiple value inflection points through at least Q1 2024 1 (1) Excluding potential future milestone payments; IFRS income/(loss) ▪ Net loss after taxes of CHF 16.7 million for the quarter ended March 31, 2021 compared with net loss of CHF 7.7 million for 2020

8. Strategic outlook

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Drivers of value creation in 2021 and beyond 35 Sustained financial strength ▪ Strong balance sheet with potential for substantial partnership revenue ▪ Vision to become a fully integrated biopharmaceutical company Enabling platforms ▪ Morphomer ® and SupraAntigen ® ▪ Fuel development pipeline and create growth opportunities Clear execution strategy ▪ Late - stage development in Alzheimer’s disease (AD) with partners ▪ Non - AD focused on DS - AD 1 , PD 2 , and NeuroOrphan indications ▪ Companion diagnostics Precision medicine ▪ Integrated diagnostics and therapeutics ▪ Enables targeted single and/or combination therapies Superior Science ▪ First - or best - in - class candidates ▪ Long - term value creation through in - house development and strategic partnership (1) Down syndrome - related AD; (2 ) Parkinson’s disease

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 36 (1) Central nervous system; (2) Limbic - predominant age - related TDP - 43 encephalopathy AC Immune future directions Expanding our capabilities and building a fully - integrated company Inflammation in non - CNS indications Parkinson’s disease LATE 2 NeuroOrphan Alzheimer’s Disease CNS 1 - targeted diagnostics Neuroinflammation Future Directions Current Focus Fully integrated biotech company Wholly - owned late - stage clinical assets Commercial capability

NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission We continue to shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine 37 AC Immune